echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Digestive System Information > Brit J Cancer: Analysis of the efficacy of metformin in the treatment of resophageal colorectal cancer in the same group

    Brit J Cancer: Analysis of the efficacy of metformin in the treatment of resophageal colorectal cancer in the same group

    • Last Update: 2021-01-17
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Patients with resoic colorectal cancer (CRC) have few effective treatment options.
    recently, a study published in British Journal of Cancer, an authoritative journal in the field of oncology, was designed to test the efficacy of metformin and elixir combination therapy in such patients.
    researchers conducted a two-phase single-group trial in which patients were given 2,500 mg of metformin daily or oral, and 125 mg/m2 of intravenously, once a week.
    the study was the disease control rate at 12 weeks based on the Version 1.1 Solid Tumor Response Assessment Standard.
    between December 2015 and January 2018, researchers recruited 41 patients.
    17 patients (41 percent) reached the main end of disease control in 12 weeks.
    participants had a non-progressed lifetime of 3.3 months (95% CI for 2.0-4.5 months) and a total participant survival period of 8.4 months (95% CI for 5.9-10.8 months).
    in the multivariate model, both RAS mutation status and disease control at 12 weeks affected the participants' total survival rate (HR was 2.28, 95% CI was 1.12-4.7, p=0.02; HR was 0.21, 95% CI was 0.08-0.5, p=0.001).
    most common adverse events were diarrhoea (29.2% of participants had level 3 diarrhea).
    in this trial, patients with resophedic CRC were treated with metformin and erythyroid to achieve disease control.
    further optimized diarrhea control tests are needed to confirm these results.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.